Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Up to $30.34

Zealand Pharma A/S (NASDAQ:ZEAL)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $30.34, but opened at $31.27. Zealand Pharma A/S shares last traded at $31.27, with a volume of 60 shares.

Separately, Zacks Investment Research cut shares of Zealand Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, March 17th.

The company has a market cap of $1.40 billion, a P/E ratio of -14.11 and a beta of 1.19. The business’s 50 day simple moving average is $32.00 and its 200 day simple moving average is $35.68.

Zealand Pharma A/S (NASDAQ:ZEAL) last released its earnings results on Wednesday, March 10th. The company reported ($9.76) EPS for the quarter, missing analysts’ consensus estimates of ($5.90) by ($3.86). Zealand Pharma A/S had a negative return on equity of 38.34% and a negative net margin of 214.31%. As a group, equities research analysts expect that Zealand Pharma A/S will post -2.61 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC grew its holdings in Zealand Pharma A/S by 35.5% during the 4th quarter. Jane Street Group LLC now owns 35,707 shares of the company’s stock valued at $1,283,000 after buying an additional 9,352 shares in the last quarter. Morgan Stanley grew its holdings in Zealand Pharma A/S by 4.5% during the 3rd quarter. Morgan Stanley now owns 8,360 shares of the company’s stock valued at $321,000 after buying an additional 357 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Zealand Pharma A/S by 320.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 958 shares of the company’s stock valued at $36,000 after buying an additional 730 shares in the last quarter. 4.32% of the stock is owned by institutional investors and hedge funds.

Zealand Pharma A/S Company Profile (NASDAQ:ZEAL)

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua.

Read More: What is the S&P 500 Index?

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.